|
Volumn 38, Issue 3, 2011, Pages 266-267
|
Managing cardiac risk factors in oncology clinical trials
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTHRACYCLINE;
BEVACIZUMAB;
SORAFENIB;
SUNITINIB;
TRASTUZUMAB;
VASCULOTROPIN;
VASCULOTROPIN INHIBITOR;
VERUBULIN;
ARTICLE;
BRADYCARDIA;
BREAST CANCER;
CARDIOTOXICITY;
CARDIOVASCULAR RISK;
CLINICAL TRIAL (TOPIC);
DRUG WITHDRAWAL;
HEART ATRIUM FIBRILLATION;
HEART DISEASE;
HEART FAILURE;
HEART INFARCTION;
HEART LEFT VENTRICLE FUNCTION;
HEART LEFT VENTRICLE SYSTOLIC DYSFUNCTION;
HUMAN;
HYPERTENSION;
ONCOLOGY;
PATIENT MONITORING;
QT PROLONGATION;
RISK FACTOR;
TACHYCARDIA;
THROMBOEMBOLISM;
TUMOR VASCULARIZATION;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
EARLY DIAGNOSIS;
HEART DISEASES;
HUMANS;
NEOPLASMS;
PROGNOSIS;
RESEARCH DESIGN;
RISK ASSESSMENT;
RISK FACTORS;
|
EID: 79959972699
PISSN: 07302347
EISSN: 15266702
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (5)
|
References (5)
|